Insmed Discontinues Brensocatib HS Program After Phase 2b CEDAR Study Misses All Endpoints
Insmed’s HS drug failed to beat placebo in a mid-stage trial, though it was safe. Development for this condition has been stopped.
/ 5 items
#INSM↓
Morgan Stanley Boosts Insmed on Strong Brinsupri Outlook
Morgan Stanley upgrades Insmed to Overweight and raises price target to $212.
Insmed’s Arikayce Scores Big Win in Phase 3 Study – Could Soon Treat Early-Stage MAC Lung Disease
Insmed announced positive topline results from the Phase 3b ENCORE study of Arikayce in newly diagnosed MAC lung disease. The drug showed statistically significant improvements in respiratory symptoms and culture conversion rates vs standard therapy.
Jefferies Goes All-In on Biotech: 5 Buy-Rated Stocks Poised for Big 2026 Catalysts
Jefferies initiates Buy on Design Therapeutics ($15 PT) & assumes coverage on Revolution Medicines ($140), Kymera ($110), Immatics ($18), Insmed ($228).
Insmed Halts Sinus Treatment, Acquires New Drug Candidate
Insmed discontinues brensocatib for chronic sinus disease after failed trial but adds promising antibody therapy INS1148 to its pipeline for lung and immune conditions.